ED
MJN

Exane Derivatives’s Mead Johnson Nutrition Company MJN Stock Holding History

Exane Derivatives’s Portfolio MJN Stock Details MJN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-43,633
Closed -$4.39M – 574
2014
Q4 		$4.39M Buy
+43,633
New +$4.35M 0.61% 45

Other funds holding MJN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Exane Derivatives's MJN Position: Q1 2015 in Review

Exane Derivatives sold out of Mead Johnson Nutrition Company (MJN) in Q1 2015, closing a stake of 43,633 shares — an estimated $4.39M sold.

Exane Derivatives first reported a position in MJN in Q4 2014 and held it in 1 quarter. The position peaked at $4.39M in Q4 2014. 547 funds tracked by Wall St. Rank hold MJN as of Q1 2015.

  • Exane Derivatives reported no remaining Mead Johnson Nutrition Company position as of Q1 2015 after selling out during the quarter.
  • Exane Derivatives sold 43,633 Mead Johnson Nutrition Company shares in Q1 2015, an estimated $4.39M.
  • Exane Derivatives first reported a position in Mead Johnson Nutrition Company in Q4 2014 and held it in 1 quarter.
  • Exane Derivatives's Mead Johnson Nutrition Company position peaked at $4.39M in Q4 2014.
  • 547 funds tracked by Wall St. Rank held Mead Johnson Nutrition Company as of Q1 2015.

Based on Exane Derivatives's 13F filing for Q1 2015, filed 15 May 2015.